The efficiency and safety of Methylpredinisolone combined with low-dose corticosteroid on the treatment of patients with IgAN

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800014442

Enrollment

Unknown

Registered

2018-01-13

Start date

2018-01-15

Completion date

Unknown

Last updated

2022-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

Methylpredinisolne pluse:Methylpredinisolne pluse therapy+low dose oral glucocorticoids

Sufficient corticosteroids:Sufficient corticosteroids

Eligibility

Sex/Gender

All

Age

15 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of IgAN by renal biopsy; 2. Aged 15 to 75 years; 3. Proteinuria between 1.0g/24h-3.5g/24h after supportive treatment; 4. Plasma creatinine <= 171mol/L (2 mg/dL).

Exclusion criteria

Exclusion criteria: Exclusion criteria were treatment with steroids or cytotoxic drugs during the previous 3 years, pregnancy, or clinical or biological evidence of Henoch-Schinlein purpura, lupus erythematosus, diabetes mellitus, neoplasia, active peptic-ulcer disease, viral hepatitis, or other infections.

Design outcomes

Primary

Measure	Time frame
24 hours urinary protein;eGFR;cCr;albumin;triglycerides;cholesterol;Fasting plasma glucose;Uric acid;blood routine test;routine urine;BUN;	—

Countries

China

Contacts

Public ContactFu Rong-Guo

The Second Affiliated Hospital of Xi'an JiaoTong University

pipifu@126.com+86 15291185506

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026